Royce & Associates LP acquired a new position in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,292,800 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,814,000. Royce & Associates LP owned 2.31% of BioDelivery Sciences International at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Advisor Group Inc. grew its holdings in BioDelivery Sciences International by 42.1% during the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after acquiring an additional 13,341 shares during the period. Valley National Advisers Inc. grew its holdings in BioDelivery Sciences International by 59.0% in the second quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock valued at $106,000 after purchasing an additional 14,000 shares during the last quarter. Stonepine Capital Management LLC grew its holdings in BioDelivery Sciences International by 22.2% in the second quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock valued at $9,737,000 after purchasing an additional 632,853 shares during the last quarter. GSA Capital Partners LLP grew its holdings in BioDelivery Sciences International by 10.1% in the second quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock valued at $1,369,000 after purchasing an additional 44,700 shares during the last quarter. Finally, EAM Investors LLC acquired a new stake in BioDelivery Sciences International in the second quarter valued at $1,348,000. 44.18% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BioDelivery Sciences International, Inc. (BDSI) opened at $2.80 on Tuesday. The company has a quick ratio of 1.07, a current ratio of 1.28 and a debt-to-equity ratio of 1.89. BioDelivery Sciences International, Inc. has a twelve month low of $1.55 and a twelve month high of $3.60.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The company had revenue of $11.25 million for the quarter, compared to analyst estimates of $9.40 million. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. BioDelivery Sciences International’s revenue was up 215.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.30) earnings per share. sell-side analysts predict that BioDelivery Sciences International, Inc. will post 0.16 EPS for the current year.

Several research firms have weighed in on BDSI. HC Wainwright set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Friday, October 13th. ValuEngine lowered BioDelivery Sciences International from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Roth Capital set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Thursday, October 12th. Cantor Fitzgerald set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Thursday, October 12th. Finally, Piper Jaffray Companies set a $4.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Sunday, October 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $4.29.

In related news, CEO Mark A. Sirgo sold 65,405 shares of the stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $2.75, for a total transaction of $179,863.75. Following the sale, the chief executive officer now owns 1,509,262 shares of the company’s stock, valued at $4,150,470.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Mark A. Sirgo sold 201,373 shares of the stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $2.84, for a total value of $571,899.32. Following the sale, the insider now directly owns 1,509,262 shares in the company, valued at approximately $4,286,304.08. The disclosure for this sale can be found here. 9.00% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Royce & Associates LP Takes Position in BioDelivery Sciences International, Inc. (BDSI)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/royce-associates-lp-takes-position-in-biodelivery-sciences-international-inc-bdsi/1772233.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.